FibroMAX ™:: towards a new universal biomarker of liver disease?

被引：41

作者：

Morra, Rachel ^{[1
]}

Munteanu, Mona ^{[1
]}

Imbert-Bismut, Francoise ^{[1
]}

Messous, Djamila ^{[1
]}

Ratziu, Wad ^{[1
]}

Poynard, Thierry ^{[1
]}

机构：

[1] Hop La Pitie Salpetriere, F-75651 Paris, France

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2007年 / 7卷 / 05期

关键词：

ActiTest((TM)); activity biomarker; alcoholic liver disease; AshTest((TM)); fatty liver; FibroSURE((TM)); FibroTest((TM)); HBV; HCV; liver biopsy limit; NashTest((TM)); nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; steatohepatitis biomarker; steatosis biomarker; SteatoTest((TM));

D O I：

10.1586/14737159.7.5.481

中图分类号：

R36 [病理学];

学科分类号：

100104 [病理学与病理生理学];

摘要：

Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the predictive value and a better benefit-to-risk ratio than biopsy of five combinations of simple serum biochemical markers (the super combination being FibroMAX(TM) (BioPredictive, Paris, France) in patients at risk of chronic liver diseases: FibroTest(TM) (BioPredictive) for the quantitative assessment of fibrosis; SteatoTest(TM) (BioPredictive) for the quantitative assessment of steatosis; ActiTest(TM) (BioPredictive) for the quantitative assessment of necroinflammatory activity in chronic viral hepatitis C and B; NashTest(TM) (BioPredictive) for the categorical diagnosis of nonalcoholic steatohepatitis; and AshTes(TM) for the quantitative assessment of alcoholic steatohepatitis (also known in the USA as HCV-FibroSURE(TM), HBV-FibroSURE(TM), ASH-FibroSURE(TM) and NASH-FibroSURE(TM); LabCorp, NC, USA). The possible causes of false-negative and false-positive results are also better identified. These tests, which are now available in 50 countries, can facilitate the screening and management of the most frequent liver diseases.

引用

页码：481 / 490

页数：10

共 62 条

[1]

Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection [J].